235 related articles for article (PubMed ID: 25315681)
1. PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper.
Aboud AA; Tidball AM; Kumar KK; Neely MD; Han B; Ess KC; Hong CC; Erikson KM; Hedera P; Bowman AB
Neurobiol Dis; 2015 Jan; 73():204-12. PubMed ID: 25315681
[TBL] [Abstract][Full Text] [Related]
2. Genetic risk for Parkinson's disease correlates with alterations in neuronal manganese sensitivity between two human subjects.
Aboud AA; Tidball AM; Kumar KK; Neely MD; Ess KC; Erikson KM; Bowman AB
Neurotoxicology; 2012 Dec; 33(6):1443-1449. PubMed ID: 23099318
[TBL] [Abstract][Full Text] [Related]
3. The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.
Gautier CA; Erpapazoglou Z; Mouton-Liger F; Muriel MP; Cormier F; Bigou S; Duffaure S; Girard M; Foret B; Iannielli A; Broccoli V; Dalle C; Bohl D; Michel PP; Corvol JC; Brice A; Corti O
Hum Mol Genet; 2016 Jul; 25(14):2972-2984. PubMed ID: 27206984
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
Imaizumi Y; Okada Y; Akamatsu W; Koike M; Kuzumaki N; Hayakawa H; Nihira T; Kobayashi T; Ohyama M; Sato S; Takanashi M; Funayama M; Hirayama A; Soga T; Hishiki T; Suematsu M; Yagi T; Ito D; Kosakai A; Hayashi K; Shouji M; Nakanishi A; Suzuki N; Mizuno Y; Mizushima N; Amagai M; Uchiyama Y; Mochizuki H; Hattori N; Okano H
Mol Brain; 2012 Oct; 5():35. PubMed ID: 23039195
[TBL] [Abstract][Full Text] [Related]
5. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
6. Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism.
Okarmus J; Havelund JF; Ryding M; Schmidt SI; Bogetofte H; Heon-Roberts R; Wade-Martins R; Cowley SA; Ryan BJ; Færgeman NJ; Hyttel P; Meyer M
Stem Cell Reports; 2021 Jun; 16(6):1510-1526. PubMed ID: 34048689
[TBL] [Abstract][Full Text] [Related]
7. Parkin deficiency exacerbate ethanol-induced dopaminergic neurodegeneration by P38 pathway dependent inhibition of autophagy and mitochondrial function.
Hwang CJ; Kim YE; Son DJ; Park MH; Choi DY; Park PH; Hellström M; Han SB; Oh KW; Park EK; Hong JT
Redox Biol; 2017 Apr; 11():456-468. PubMed ID: 28086194
[TBL] [Abstract][Full Text] [Related]
8. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
Hattori N
Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines.
Shaltouki A; Sivapatham R; Pei Y; Gerencser AA; Momčilović O; Rao MS; Zeng X
Stem Cell Reports; 2015 May; 4(5):847-59. PubMed ID: 25843045
[TBL] [Abstract][Full Text] [Related]
10. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation.
Ishikawa KI; Okuzumi A; Yoshino H; Hattori N; Akamatsu W
Stem Cell Res; 2024 Apr; 76():103323. PubMed ID: 38309147
[TBL] [Abstract][Full Text] [Related]
11. S-Nitrosylation of PINK1 Attenuates PINK1/Parkin-Dependent Mitophagy in hiPSC-Based Parkinson's Disease Models.
Oh CK; Sultan A; Platzer J; Dolatabadi N; Soldner F; McClatchy DB; Diedrich JK; Yates JR; Ambasudhan R; Nakamura T; Jaenisch R; Lipton SA
Cell Rep; 2017 Nov; 21(8):2171-2182. PubMed ID: 29166608
[TBL] [Abstract][Full Text] [Related]
12. The
Ming F; Tan J; Qin L; Zhang H; Tang J; Tan X; Wang C
Biomed Res Int; 2020; 2020():4658109. PubMed ID: 33029508
[TBL] [Abstract][Full Text] [Related]
13. Parkin and PINK1 Patient iPSC-Derived Midbrain Dopamine Neurons Exhibit Mitochondrial Dysfunction and α-Synuclein Accumulation.
Chung SY; Kishinevsky S; Mazzulli JR; Graziotto J; Mrejeru A; Mosharov EV; Puspita L; Valiulahi P; Sulzer D; Milner TA; Taldone T; Krainc D; Studer L; Shim JW
Stem Cell Reports; 2016 Oct; 7(4):664-677. PubMed ID: 27641647
[TBL] [Abstract][Full Text] [Related]
14. Generation of a PARK2 homozygous knockout induced pluripotent stem cell line (GIBHi002-A-1) with two common isoforms abolished.
Zhang M; Ibañez DP; Fan W; Liu H; Zhong X; Wang X; Li Y; Md Abdul M; Li W; Li Y; Ward C; Chen S; Wang D; Qin B; Esteban MA; Zhao P; Luo Z
Stem Cell Res; 2019 Dec; 41():101602. PubMed ID: 31698191
[TBL] [Abstract][Full Text] [Related]
15. PARK2 gene mutations in early onset Parkinson's disease patients of South India.
Padmaja MV; Jayaraman M; Srinivasan AV; Srisailapathy CR; Ramesh A
Neurosci Lett; 2012 Aug; 523(2):145-7. PubMed ID: 22766139
[TBL] [Abstract][Full Text] [Related]
16. Generation of three induced pluripotent stem cell lines from a Parkinson's disease patient with mutant PARKIN (p. C253Y).
Tariq M; Liu H; Ibañez DP; Li Y; Chen S; Jiang M; Fan W; Zhao P; Luo Z; Wang D; Kanwal S
Stem Cell Res; 2020 May; 45():101822. PubMed ID: 32387897
[TBL] [Abstract][Full Text] [Related]
17. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
18. PARK2 variability in Polish Parkinson's disease patients--interaction with mitochondrial haplogroups.
Gaweda-Walerych K; Safranow K; Jasinska-Myga B; Bialecka M; Klodowska-Duda G; Rudzinska M; Czyzewski K; Cobb SA; Slawek J; Styczynska M; Opala G; Drozdzik M; Nishioka K; Farrer MJ; Ross OA; Wszolek ZK; Barcikowska M; Zekanowski C
Parkinsonism Relat Disord; 2012 Jun; 18(5):520-4. PubMed ID: 22361577
[TBL] [Abstract][Full Text] [Related]
19. Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons.
Suzuki S; Akamatsu W; Kisa F; Sone T; Ishikawa KI; Kuzumaki N; Katayama H; Miyawaki A; Hattori N; Okano H
Biochem Biophys Res Commun; 2017 Jan; 483(1):88-93. PubMed ID: 28057485
[TBL] [Abstract][Full Text] [Related]
20. Generation of an induced pluripotent stem cell line (CSC-44) from a Parkinson's disease patient carrying a compound heterozygous mutation (c.823C>T and EX6 del) in the PARK2 gene.
Marote A; Pomeshchik Y; Goldwurm S; Collin A; Lamas NJ; Pinto L; Salgado AJ; Roybon L
Stem Cell Res; 2018 Mar; 27():90-94. PubMed ID: 29353703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
